Brivaracetam

Brivaracetam is a pivotal antiepileptic API and reference standard in the pharmaceutical industry, distinguished by its remarkably high affinity for the SV2A target. The superior binding affinity of Brivaracetam — 15 to 30 times that of levetiracetam — translates into enhanced clinical efficacy at lower doses, making it a valuable therapeutic option for patients with partial-onset seizures. In quality control and regulatory contexts, Brivaracetam is supplied with comprehensive characterization data for analytical method development, method validation (AMV), and quality control applications. The unique gamma-lactam scaffold of Brivaracetam continues to serve as a template for medicinal chemistry research exploring novel anticonvulsant agents and SV2A-targeting therapeutics.

 

Product Parameters

---

Parameter	Specification
Product Name	Brivaracetam
CAS Number	357336-20-0
Molecular Formula	C₁₁H₂₀N₂O₂
Molecular Weight	212.29 g/mol
Appearance	White powder
Melting Point	76.38 °C
Boiling Point	409.3 ± 28.0 °C
Storage Condition	Refrigerator

 

Indication

---

Brivaracetam is a highly selective and affinity-rich ligand for synaptic vesicle protein 2A, approved for the adjunctive treatment of partial seizures in adult and adolescent patients aged 16 years or older with epilepsy, with or without secondary generalized seizures.

 

Main Function

---

Brivaracetam exhibits high affinity for selective binding to synaptic vesicle protein 2A (SV2A), the action site of the antiepileptic drug levetiracetam. SV2A is located on the presynaptic membrane and participates in regulating neurotransmitter release and vesicle recycling, thereby maintaining normal synaptic vesicle function. Binding of brivaracetam to SV2A reduces the release of excitatory neurotransmitters and controls epileptic seizures by modulating the balance between excitatory and inhibitory neurotransmitters in the brain. The affinity of brivaracetam is 15–30 times that of levetiracetam, resulting in a approximately 10-fold reduction in required dosage.

 

Application

---

Brivaracetam is a next-generation antiepileptic drug approved by the FDA for the treatment of focal seizures in patients aged 16 years and older, as well as for use in laboratory research and pharmaceutical development processes.

 

Contact Us

---

Whether you require Brivaracetam for commercial API production, analytical method development, or regulatory filing support, Cosperpharm delivers the quality and service you need. Contact our team today — we respond within 2 business hours.